Gwak Hongki, Lim Seung-Taek, Jeon Ye-Won, Park Hyung Soon, Kim Seong Hwan, Suh Young-Jin
Division of Breast and Thyroid Surgical Oncology, Department of Surgery, Hwahong Hospital, Suwon 16630, Republic of Korea.
Division of Breast and Thyroid Surgical Oncology, Department of Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of Korea.
J Clin Med. 2022 Nov 29;11(23):7053. doi: 10.3390/jcm11237053.
Chemotherapy-induced febrile neutropenia (FN) is a medical emergency that causes severe adverse effects and death. Respiratory infections are one of the main causes of fever in patients with FN. We studied whether infection prevention and control (IPC) guidance for coronavirus 2019 disease reduced the incidence of FN. We reviewed female patients with breast cancer treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide with prophylactic pegfilgrastim between 2019 and 2021. IPC guidance was implemented in April 2020. There was no difference in the incidence of chemotherapy-induced neutropenia between patients with and without IPC. In patients with IPC, the incidence of FN (9.5%) was lower than that of patients without IPC (27.9%). The hospitalization duration (0.7 ± 1.5 days) and total hospital cost (279.6 ± 42.6 USD) of the IPC group were significantly lower than that of the non-IPC group (2.0 ± 3.8 days and 364.7 ± 271.6 USD, respectively). IPC guidance should be implemented to prevent FN in high-risk patients with breast cancer.
化疗引起的发热性中性粒细胞减少症（FN）是一种会导致严重不良反应和死亡的医疗急症。呼吸道感染是FN患者发热的主要原因之一。我们研究了针对2019冠状病毒病的感染预防与控制（IPC）指南是否能降低FN的发生率。我们回顾了2019年至2021年间接受辅助多西他赛、阿霉素和环磷酰胺治疗并预防性使用培非格司亭的乳腺癌女性患者。IPC指南于2020年4月实施。有IPC和没有IPC的患者化疗引起的中性粒细胞减少症发生率没有差异。在有IPC的患者中，FN的发生率（9.5%）低于没有IPC的患者（27.9%）。IPC组的住院时间（0.7±1.5天）和总住院费用（279.6±42.6美元）显著低于非IPC组（分别为2.0±3.8天和364.7±271.6美元）。应实施IPC指南以预防高危乳腺癌患者发生FN。
